S&P Futures
4,265.25 -11.50 (-0.27%) Dow Futures
33,897.00 -66.00 (-0.19%) Nasdaq Futures
13,444.00 -49.25 (-0.36%) Russell 2000 Futures
1,986.30 -2.80 (-0.14%) Crude Oil
87.73 -0.38 (-0.43%) Gold
1,775.90 -0.80 (-0.05%)
Asensus Surgical, Inc. (ASXC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.7300 |
| Open | 0.7162 |
| Bid | 0.0000 x 3100 |
| Ask | 0.0000 x 1400 |
| Day's Range | 0.6600 - 0.7243 |
| 52 Week Range | 0.3500 - 2.3700 |
| Volume | |
| Avg. Volume | 2,522,390 |
| Market Cap | 162.153M |
| Beta (5Y Monthly) | 1.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2740 |
| Earnings Date | Nov 01, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ASXC
Related Research
- Asensus Surgical, Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat10 days agoMorningstar
- GlobeNewswire
Asensus Surgical, Inc. Reports Operating and Financial Results for the Second Quarter 2022
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the second quarter 2022. Recent Highlights Over 670 procedures were performed globally during the quarter, representing growth of 34% over the prior year quarter, including 77% growth in
- GlobeNewswire
Asensus Surgical Announces Sale of Senhance Robotic System
Senhance System to be placed at hospital in the Commonwealth of Independent States Senhance Surgical System Performance-Guided Surgery™ Leveraging the Performance-Guided Surgery™ framework, the Senhance Surgical System advances clinical intelligence by providing surgeons with augmented intelligence and digital tools to perform consistently superior surgery. RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that
- GlobeNewswire
Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 8, 2022
RESEARCH TRIANGLE PARK, N.C., July 26, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release 2022 second quarter financial and operating results after the market closes on Monday, August 8, 2022. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day.
